This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsenova, L.
Right arrow Articles by Kaplan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsenova, L.
Right arrow Articles by Kaplan, G.

 Previous Article  |  Next Article 

Infection and Immunity, April 2006, p. 2392-2401, Vol. 74, No. 4
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.4.2392-2401.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis

Liana Tsenova,1 Ryhor Harbacheuski,1 Andre L. Moreira,3 Evette Ellison,1 Wilfried Dalemans,4 Mark R. Alderson,5 Barun Mathema,2,7 Steven G. Reed,6 Yasir A. W. Skeiky,5,{dagger} and Gilla Kaplan1*

Laboratory of Mycobacterial Immunity and Pathogenesis,1 Tuberculosis Center, PHRI, Newark, New Jersey 07103,2 Memorial Sloan Kettering Cancer Center, New York, New York 10021,3 GlaxoSmithKline Biologicals, Rixensart, Belgium,4 Corixa Corporation, Seattle, Washington 98104,5 Infectious Disease Research Institute, Seattle, Washington 98104,6 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 100327

Received 12 September 2005/ Returned for modification 9 November 2005/ Accepted 26 January 2006

Using a rabbit model of tuberculous meningitis, we evaluated the protective efficacy of vaccination with the recombinant polyprotein Mtb72F, which is formulated in two alternative adjuvants, AS02A and AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guérin (BCG) alone or as a BCG prime/Mtb72F-boost regimen. Vaccination with Mtb72F formulated in AS02A (Mtb72F+AS02A) or Mtb72F formulated in AS01B (Mtb72F+AS01B) was protective against central nervous system (CNS) challenge with Mycobacterium tuberculosis H37Rv to an extent comparable to that of vaccination with BCG. Similar accelerated clearances of bacilli from the cerebrospinal fluid, reduced leukocytosis, and less pathology of the brain and lungs were noted. Weight loss of infected rabbits was less extensive for Mtb72F+AS02A-vaccinated rabbits. In addition, protection against M. tuberculosis H37Rv CNS infection afforded by BCG/Mtb72F in a prime-boost strategy was similar to that by BCG alone. Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals.

* Corresponding author. Mailing address: Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103. Phone: (973) 854-3220. Fax: (973) 854-3222. E-mail: kaplan{at}phri.org.

Editor: J. L. Flynn

{dagger} Present address: Aeras Global TB Vaccine Foundation, Bethesda, MD 20814.

Infection and Immunity, April 2006, p. 2392-2401, Vol. 74, No. 4
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.4.2392-2401.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Goldstone, R. M., Goonesekera, S. D., Bloom, B. R., Sampson, S. L. (2009). The Transcriptional Regulator Rv0485 Modulates the Expression of a pe and ppe Gene Pair and Is Required for Mycobacterium tuberculosis Virulence. Infect. Immun. 77: 4654-4667 [Abstract] [Full Text]  
  • Reed, S. G., Coler, R. N., Dalemans, W., Tan, E. V., DeLa Cruz, E. C., Basaraba, R. J., Orme, I. M., Skeiky, Y. A. W., Alderson, M. R., Cowgill, K. D., Prieels, J.-P., Abalos, R. M., Dubois, M.-C., Cohen, J., Mettens, P., Lobet, Y. (2009). Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 106: 2301-2306 [Abstract] [Full Text]  
  • Rock, R. B., Olin, M., Baker, C. A., Molitor, T. W., Peterson, P. K. (2008). Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects. Clin. Microbiol. Rev. 21: 243-261 [Abstract] [Full Text]  
  • Hebert, A. M., Talarico, S., Yang, D., Durmaz, R., Marrs, C. F., Zhang, L., Foxman, B., Yang, Z. (2007). DNA Polymorphisms in the pepA and PPE18 Genes among Clinical Strains of Mycobacterium tuberculosis: Implications for Vaccine Efficacy. Infect. Immun. 75: 5798-5805 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»